How much of a market is involved in a biodiversity offset? A typology of biodiversity offset policies.

07:00 EST 3rd December 2018 | BioPortfolio

Summary of "How much of a market is involved in a biodiversity offset? A typology of biodiversity offset policies."

Biodiversity offsets (BO) are increasingly promoted and adopted by governments and companies worldwide as a policy instrument to compensate for biodiversity losses from infrastructure development projects. BO are often classified as 'market-based instruments' both by proponents and critics, but this representation fails to capture the varieties of how BO policies actually operate. To provide a framing for understanding the empirical diversity of BO policy designs, we present an ideal-typical typology based on the institutions from which BO is organised: Public Agency, Mandatory Market and Voluntary Offset. With cross-case comparison and stakeholder mapping, we identified the institutional arrangements of six BO policies to analyse how the biodiversity losses and gains are decided. Based on these results, we examined how these six policies relate to the BO ideal types. Our results suggested that the government, contrary to received wisdom, plays a key role not just in enforcing mandatory policies but also in determining the supply and demand of biodiversity units, supervising the transaction or granting legitimacy to the compensation site. Mandatory BO policies can be anything from pure government regulations defining industry liabilities to liability-driven markets where choice sets for trading credits are constrained and biodiversity credit prices are negotiated under state supervision. It is important to distinguish between two processes in
the matching of biodiversity losses and gains (commensurability) and the trading of biodiversity credits (commodification). We conclude that the commensurability of natural capital is restricted in BO policies; biodiversity is always exchanged with biodiversity. However, different degrees of commodification are possible, depending on the policy design and role of price signals in trading credits. Like payments for ecosystem services, the price of a biodiversity credit is most commonly based on the cost of management measures rather than the 'value' of biodiversity; which corresponds to a low degree of commodification.


Journal Details

This article was published in the following journal.

Name: Journal of environmental management
ISSN: 1095-8630
Pages: 679-691


DeepDyve research library

PubMed Articles [5979 Associated PubMed Articles listed on BioPortfolio]

Accounting for no net loss: A critical assessment of biodiversity offsetting metrics and methods.

Biodiversity offset strategies are based on the explicit calculation of both losses and gains necessary to establish ecological equivalence between impact and offset areas. Given the importance of qua...

No net loss for people and biodiversity.

Governments, businesses, and lenders worldwide are adopting an objective of no net loss (NNL) of biodiversity that is often partly achieved through biodiversity offsetting within a hierarchy of mitiga...

The positive carbon stocks - biodiversity relationship in forests: co-occurrence and drivers across five sub-climates.

Carbon storage in forests and its ability to offset global greenhouse gas emissions, as well as biodiversity and its capacity to support ecosystem functions and services are often considered separatel...

Does a fixed offset hemiarthroplasty implant have any effect on pain and function in patients with a femoral neck fracture?

Hip hemiarthroplasty is the commonest operation performed for a displaced intracapsular hip fracture in the UK. A variety of implants including fixed offset prostheses are utilised. There has been no ...

Methane emissions partially offset "blue carbon" burial in mangroves.

Organic matter burial in mangrove forests results in the removal and long-term storage of atmospheric CO, so-called "blue carbon." However, some of this organic matter is metabolized and returned to t...

Clinical Trials [1931 Associated Clinical Trials listed on BioPortfolio]

The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study

What is the role of Agricultural biodiversity in improving diet diversity, quality and nutrition?

Knee Posterior Femoral Condylar Offset and Tibial Slope of the Egyptian Population

this study is to compare the posterior condylar offset , posterior condylar offset ratio and tibial slope of Egyptian population with Asian and Western results.These results may be importa...

Comparing The Outcome of Large-Diameter vs Small-Diameter Glenospheres in Primary Reverse Shoulder Arthroplasty

The study will compare the outcome of primary reverse shoulder arthroplasty using the Stryker ReUnion System with implantation of either a large (40 mm) or a small (36 mm) glenosphere with...

Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty

The purpose of this study is to prospectively evaluate two FDA approved implant designs for the Tornier Reverse Shoulder arthroplasty. The small difference in design is the amount of offse...

Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement

The investigators aim to demonstrate the ability to accurately measure and restore leg length, offset, and center of rotation during a total hip replacement through a new technique that us...

Medical and Biotech [MESH] Definitions

The variety of all native living organisms and their various forms and interrelationships.

Abnormally rapid heartbeats caused by reentry circuit in or around the SINOATRIAL NODE. It is characterized by sudden onset and offset episodes of tachycardia with a HEART RATE of 100-150 beats per minute. The P wave is identical to the sinus P wave but with a longer PR interval.

Places where animals are slaughtered and dressed for market.

A phenylacetamide that was formerly used in ANALGESICS but nephropathy and METHEMOGLOBINEMIA led to its withdrawal from the market. (From Smith and Reynard, Textbook of Pharmacology,1991, p431)

Removal of a drug from the market due to a problem occurring in the manufacture or distribution of the product.

Quick Search


DeepDyve research library

Searches Linking to this Article